

PATENT
Customer No. 22,852
Application No. 10/601,756
Attorney Docket No. 07206.0027-01000

IN THE CLAIMS:

Please cancel claims 1-11, without prejudice or disclaimer of the subject matter recited therein and enter new claims 12-19 as follows:

12. (New) A method of treating a patient suffering from at least one inflammatory condition selected from ulcerative colitis, Crohn's disease, proctitis, microscopic colitis, allergic eosinophilic gastroenteritis, food allergies, pill induced esophagitis, celiac disease, recurrent polyps, and hemorrhoids; wherein the method comprises administering to the patient a therapeutically effective amount of at least one progesterone analog selected from an acetophenone derivative of 16 α , 17 α -dihydroxyprogesterone, allylestrenol, chlormadinone acetate, cyproterone acetate, desogestrel, dimethisterone, dydrogesterone, estrenols, ethinylestrenol, ethlestrenol, ethynodiol diacetate, hydroxyprogesterone caproate, megestrol acetate, norethandrolone, norethynodrel, norgestimate, 19-nortestosterone, valerate, caproate esters of progesterone, and any physiologically tolerated salts thereof.

13. (New) The method of claim 12, wherein the progesterone analog exhibits progestational activity.

14. (New) The method of claim 12, wherein the progesterone analog is administered to the patient once a day.

15. (New) The method of claim 12, wherein the amount of progesterone analog administered to the patient is about 500 mg to about 2 grams per day.

PATENT
Customer No. 22,852
Application No. 10/601,756
Attorney Docket No. 07206.0027-01000

16. (New) The method of claim 12, wherein the progesterone analog is administered orally.

17. (New) The method of claim 12, wherein the patient is suffering from ulcerative colitis or Crohn's disease.

18. (New) The method of claim 12, wherein the progesterone analog is formulated in an enteric coated tablet to allow for targeted delivery to an affected portion of the gastrointestinal tract.

19. (New) The method of claim 18, wherein the progesterone analog is administered rectally using an enema, a suppository, a foam, a cream, a gel, an ointment, a suspension, or combinations thereof.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com